For the latest updates on our ongoing response to COVID-19, please click here.

                        Company Statements

                        04/10/2020

                        Gilead Sciences Response to Médecins Sans Frontières

                        03/25/2020

                        Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

                        03/23/2020

                        Gilead Sciences Statement on Ensuring Continued  Supply of HIV Medicine Amid Coronavirus Outbreak

                        03/22/2020

                        Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

                        02/05/2020

                        Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

                        01/31/2020

                        Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

                        12/03/2019

                        Gilead Statement on Commitment to Advancing Descovy for PrEP? Study in Cisgender Women & Adolescent Females

                        11/07/2019

                        Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

                        08/21/2019

                        Petitions to US Patent and Trademark Office on HIV PrEP Patents

                        06/11/2019

                        Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

                        05/14/2019

                        Gilead Sciences Statement On Inaccurate Reporting On Truvada®

                        04/10/2019

                        Gilead Sciences Statement on Commitment to Providing Price Information

                        04/04/2019

                        Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025

                        04/03/2019

                        Gilead Sciences Announces $500,000 Grant To Pan American Development Foundation To Provide Emergency Health Services For Venezuelan Migrants And Host Communities In Colombia

                        09/27/2018

                        Gilead Sciences Statement on Grants to Spouses of Caricom Leaders Action Network (SCLAN) to Expand Access to Youth HIV Prevention and Care in the Caribbean

                        09/24/2018

                        A perspective from our CEO: Gilead Subsidiary to Launch Authorized Generics to Treat HCV

                        09/07/2018

                        Gilead Sciences Announces Steep Discounts for Ambisome to Treat Cryptococcal Meningitis in Low- and Middle-Income Countries

                        05/02/2018

                        Gilead Publishes 2017 Year in Review

                        11/09/2017

                        Gilead Sciences Announces 100 Percent Score on 2018 Human Rights Campaign Corporate Equality Index

                        09/01/2017

                        Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access

                        05/01/2017

                        Gilead Publishes Year in Review 2016

                        12/06/2016

                        Gilead Recognized as Top Corporate Philanthropist in Funders Concerned About AIDS Report

                        12/01/2016

                        Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries

                        11/11/2016

                        Statement on DISCOVER Study of F/TAF for PrEP

                        08/01/2016

                        Gilead Publishes 2015 Corporate Social Responsibility Report

                        08/14/2015

                        Gilead Supports PrEP Education to Increase HIV Prevention and Awareness

                        08/12/2015

                        Gilead Publishes Its 2014 Corporate Contributions Report

                        Some of the content on this page is not intended for users outside the US.

                        三级黄片